BAF312 (siponimod)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BAF312 (siponimod), covering 2017-12-12 to 2017-12-12. Get the full timeline:
Most recent: Clinical Trial Update: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]